MRK reports blowout results for Keytruda/Inlyta in 1L-RCC: https://www.businesswire.com/news/home/20190211005764/en/Merck-Highlights-Breadth-Immuno-Oncology-Research-Program-Genitourinary http://www.evaluate.com/vantage/articles/news/trial-results/asco-gu-bristols-renal-cancer-lead-looks-be-short-lived https://twitter.com/AndyBiotech/status/1095078973153951744